Evidence map›Paper›PMID 31440738›Full record

ArticleJCO precision oncology2019

Genomic Correlates of Exceptional Response to ErbB3 Inhibition in Head and Neck Squamous Cell Carcinoma.

Daniel L Faden, Roberto Gomez-Casal, Diego Alvarado, Umamaheswar Duvvuri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Daniel L FadenMassachusetts Eye and Ear, Boston, MA.
Roberto Gomez-CasalUniversity of Pittsburgh, Pittsburgh, PA.
Diego AlvaradoCelldex Therapeutics, Hampton, NJ.
Umamaheswar DuvvuriUniversity of Pittsburgh, Pittsburgh, PA.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
Postdoctoral Training in Head and Neck OncologyT32CA060397 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZEVALLOS, JOSE P. · 1994 to 2024
$2.7M
Inhibition of lysosomal flux in carcinogen-induced head and neck cancerR01DE028343 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DUVVURI, UMAMAHESWAR · 2019 to 2023
$1.9M
Novel targets to treat head and neck cancer in VeteransI01BX003456 · VA · VETERANS HEALTH ADMINISTRATION · PI DUVVURI, UMAMAHESWAR · 2017 to 2021
–
BLRD VA I01 BX003456NCI NIH HHS P30 CA047904NCI NIH HHS T32 CA060397NIDCR NIH HHS R01 DE028343
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID31440738
PMCPMC6705601

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.